Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimer's Disease

Cell Reports

Volumn 10, Issue 3, 2015, Pages 359-369

  Raj, Ashish ^a   LoCastro, Eve ^a   Kuceyeski, Amy ^a   Tosun, Duygu ^b   Relkin, Norman ^a   Weiner, Michael ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; CEREBROSPINAL FLUID LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; NETWORK DIFFUSION MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TEMPORAL CORTEX; YOUNG ADULT;

EID: 84921417870     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.12.034     Document Type: Article

References (55)

1. Apostolova L.G., Thompson P.M. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia 2008, 46:1597-1612.
2. Apostolova L.G., Steiner C.A., Akopyan G.G., Dutton R.A., Hayashi K.M., Toga A.W., Cummings J.L., Thompson P.M. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch. Neurol. 2007, 64:1489-1495.
3. Braak H., Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci. Res. 1992, 15:6-31.
4. Braak H., Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 1996, 165:3-12.
5. Braak H., Del Tredici K. Where, when, and in what form does sporadic Alzheimer's disease begin?. Curr. Opin. Neurol. 2012, 25:708-714.
6. Braak H., Del Tredici K., Schultz C., Braak E. Vulnerability of select neuronal types to Alzheimer's disease. Ann. N Y Acad. Sci. 2000, 924:53-61.
7. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J.Neurosci. 2005, 25:7709-7717.
8. Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
9. Da X., Toledo J.B., Zee J., Wolk D.A., Xie S.X., Ou Y., Shacklett A., Parmpi P., Shaw L., Trojanowski J.Q., Davatzikos C. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin 2014, 4:164-173. Alzheimer's Neuroimaging Initiative.
10. Dickerson B.C., Wolk D.A. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Front Aging Neurosci 2013, 5:55. Alzheimer's Disease Neuroimaging Initiative.
11. Englund E., Brun A., Alling C. White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates. Brain 1988, 111:1425-1439.
12. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
13. Fjell A.M., Walhovd K.B. New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?. Neuroscientist 2011, 17:592-605.
14. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Blennow K., Brewer J.B., Dale A.M. Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb. Cortex 2010, 20:2069-2079. Alzheimer's Disease Neuroimaging Initiative.
15. Frost B., Diamond M.I. Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 2010, 11:155-159.
16. Frost B., Ollesch J., Wille H., Diamond M.I. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J.Biol. Chem. 2009, 284:3546-3551.
17. Goel P., Kuceyeski A., LoCastro E., Raj A. Spatial patterns of genome-wide expression profiles reflect anatomic and fiber connectivity architecture of healthy human brain. Hum. Brain Mapp. 2014, 35:4204-4218.
18. Greicius M.D., Srivastava G., Reiss A.L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl. Acad. Sci. USA 2004, 101:4637-4642.
19. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., Crain B., Hulette C., Earl N., Coleman R.E. FDG PET imaging in patients with pathologically verified dementia. J.Nucl. Med. 2000, 41:1920-1928.
20. Iturria-Medina Y., Canales-Rodríguez E.J., Melie-García L., Valdés-Hernández P.A., Martínez-Montes E., Alemán-Gómez Y., Sánchez-Bornot J.M. Characterizing brain anatomical connections using diffusion weighted MRI and graph theory. Neuroimage 2007, 36:645-660.
21. Iturria-Medina Y., Sotero R.C., Canales-Rodríguez E.J., Alemán-Gómez Y., Melie-García L. Studying the human brain anatomical network via diffusion-weighted MRI and Graph Theory. Neuroimage 2008, 40:1064-1076.
22. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365. Alzheimer's Disease Neuroimaging Initiative.
23. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
24. Jack C.R., Wiste H.J., Lesnick T.G., Weigand S.D., Knopman D.S., Vemuri P., Pankratz V.S., Senjem M.L., Gunter J.L., Mielke M.M., et al. Brain β-amyloid load approaches a plateau. Neurology 2013, 80:890-896.
25. Jucker M., Walker L.C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 2011, 70:532-540.
26. Jucker M., Walker L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013, 501:45-51.
27. Klauschen F., Goldman A., Barra V., Meyer-Lindenberg A., Lundervold A. Evaluation of automated brain MR image segmentation and volumetry methods. Hum. Brain Mapp. 2009, 30:1310-1327.
28. Kuceyeski A., Maruta J., Relkin N., Raj A. The Network Modification (NeMo) Tool: elucidating the effect of white matter integrity changes on cortical and subcortical structural connectivity. Brain Connect 2013, 3:451-463.
29. Kuczynski B., Targan E., Madison C., Weiner M., Zhang Y., Reed B., Chui H.C., Jagust W. White matter integrity and cortical metabolic associations in aging and dementia. Alzheimers Dement. 2010, 6:54-62.
30. Lafferty R.I., Kondor J. Diffusion kernels on graphs and other discrete structures. Machine Learning: Proceedings of the 19th International Conference 2002, 315-322.
31. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., Weiner M.W., Jagust W.J. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586. Alzheimer's Disease Neuroimaging Initiative.
32. Lo C.-Y., Wang P.-N., Chou K.-H., Wang J., He Y., Lin C.-P. Diffusion tensor tractography reveals abnormal topological organization in structural cortical networks in Alzheimer's disease. J.Neurosci. 2010, 30:16876-16885.
33. LoCastro E., Kuceyeski A., Raj A. Brainography: an atlas-independent surface and network rendering tool for neural connectivity visualization. Neuroinformatics 2014, 12:355-359.
34. Mattsson N., Insel P., Nosheny R., Trojanowski J.Q., Shaw L.M., Jack C.R., Tosun D., Weiner M. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol. Aging 2014, 35:614-622. Alzheimer's Disease Neuroimaging Initiative.
35. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin. N. Am. 2005, 15:869-877. xi-xii.
36. Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011, 10:785-796.
37. Palop J.J., Mucke L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
38. Palop J.J., Chin J., Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006, 443:768-773.
39. Raj A., Kuceyeski A., Weiner M. A network diffusion model of disease progression in dementia. Neuron 2012, 73:1204-1215.
40. Robinson J.L., Geser F., Corrada M.M., Berlau D.J., Arnold S.E., Lee V.M.-Y., Kawas C.H., Trojanowski J.Q. Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. Brain 2011, 134:3708-3715.
41. Rocher A.B., Chapon F., Blaizot X., Baron J.-C., Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2003, 20:1894-1898.
42. Roe C.M., Fagan A.M., Williams M.M., Ghoshal N., Aeschleman M., Grant E.A., Marcus D.S., Mintun M.A., Holtzman D.M., Morris J.C. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 2011, 76:501-510.
43. Saxena S., Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011, 71:35-48.
44. Schott J.M., Bartlett J.W., Fox N.C., Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann. Neurol. 2010, 68:825-834. Alzheimer's Disease Neuroimaging Initiative Investigators.
45. Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009, 62:42-52.
46. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Figurski M., Coart E., Blennow K., Soares H., Simon A.J., Lewczuk P., Dean R.A., et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011, 121:597-609. Alzheimer's Disease Neuroimaging Initiative.
47. Smith S.M., Jenkinson M., Woolrich M.W., Beckmann C.F., Behrens T.E.J., Johansen-Berg H., Bannister P.R., De Luca M., Drobnjak I., Flitney D.E., et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23(1):S208-S219.
48. Thompson P.M., Hayashi K.M., de Zubicaray G., Janke A.L., Rose S.E., Semple J., Herman D., Hong M.S., Dittmer S.S., Doddrell D.M., Toga A.W. Dynamics of gray matter loss in Alzheimer's disease. J.Neurosci. 2003, 23:994-1005.
49. Tosun D., Schuff N., Mathis C.A., Jagust W., Weiner M.W. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain 2011, 134:1077-1088. Alzheimer's Disease NeuroImaging Initiative.
50. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009, 73:294-301. Alzheimer's Disease Neuroimaging Initiative.
51. Villain N., Desgranges B., Viader F., de la Sayette V., Mézenge F., Landeau B., Baron J.-C., Eustache F., Chételat G. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J.Neurosci. 2008, 28:6174-6181.
52. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.
53. Whitwell J.L., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130:1777-1786.
54. Whitwell J.L., Jack C.R., Senjem M.L., Parisi J.E., Boeve B.F., Knopman D.S., Dickson D.W., Petersen R.C., Josephs K.A. MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration. Neurodegener. Dis. 2009, 6:106-117.
55. Wu M., Rosano C., Lopez-Garcia P., Carter C.S., Aizenstein H.J. Optimum template selection for atlas-based segmentation. Neuroimage 2007, 34:1612-1618.